Standard stock solution: 0.5 mg/mL of USP Alprostadil RS in dehydrated alcohol

Standard solution: 0.13 mg/mL of USP Alprostadil RS, prepared as follows. Gently evaporate a 0.5-mL portion of the Standard stock solution to dryness with a stream of nitrogen. Add 150  $\mu$ L of Solution A, rinse the inside of the container with this solution, and swirl. Add 150  $\mu$ L of Solution B to the container, rinse the inside of the container with this solution, and swirl. Cap and sonicate to dissolve. Heat the container at 45° for 45 min, swirling occasionally. Sonicate again after heating is complete. Discard the specimen if the entire sample does not dissolve. Evaporate the solution using a stream of nitrogen, add 2.0 mL of Internal standard solution, and sonicate to dissolve. Discard the specimen if the entire sample does not dissolve.

Sample solution: Nominally 0.13 mg/mL of alprostadil,

# Change to read:

• USP Reference Standards (11) USP Alprostadil RS CN 1-May-2018)

## Alteplase

SYQVICRDEK TQMIYQQHQS WLRPVLRSNR VEYCWCNSGR AQCHSVPVKS ÇSEPRĊFNGG TÇQQALYFSD FVCQCPEGFA GKCCEIDTRA TÇYEDQGISY RGTWSTAESG AECTNWNSSA LAQKPYSGRR PDAIRLGLGN HNYCRNPDRD SKPWCYVFKA GKYSSEFCST PACSEGNSDC YFGNGSAYRG THSLTESGAS CLPWNSMILI GKVYTAQNPS AQALGLGKHN YÇRNPDGDAK PWCHVLKNRR LTWEYCOVPS CSTCGLRQYS QPQFR

prepared as follows. Pool the contents of several containers of the Injection. Gently evaporate a volume, equivalent to 0.25 mg of alprostadil, to dryness using a stream of nitrogen. Proceed as directed for the Standard solution, beginning with "Add 150  $\mu$ L of Solution A". Chromatographic system

(See Chromatography (621), System Suitability.) Mode: LC

Detector: UV 254 nm

Column: 4.4-mm × 25-cm; packing L18

Flow rate: 1.5 mL/min

Injection volume: Equal volumes of Standard solution and Sample solution

System suitability

Sample: Standard solution

[NOTE—The relative retention times for ethylparaben] and alprostadil are about 0.4 and 1.0, respectively.] Suitability requirements

Resolution: NLT 9.0 between alprostadil and the internal standard

Relative standard deviation: NMT 2.5%

Analysis

**Samples:** Standard solution and Sample solution Calculate the percentage of the labeled amount of alprostadil ( $C_{20}H_{34}O_5$ ) in the portion of Injection taken:

IKGGLFADIA SHPWQAAIFA KHRRSPGERF LCGGILISSC WILSAAHCFQ ERFPPHHLTV ILGRTYRVVP GEEEQKFEVE KYIVHKEFDD DTYDNDIALL QLKSDSSRCA QESSVVRTVC LPPADLQLPD WTECELSGYG KHEALSPFYS ERLKEAHVRL YPSSRCTSQH LLNRTVTDNM LCAGDTRSGG PQANLHDACQ GDSGGPLVCL NDGRMTLVGI ISWGLGCGQK DVPGVYTKVT NYLDWIRDNM

#### C<sub>2569</sub>H<sub>3894</sub>N<sub>746</sub>O<sub>781</sub>S<sub>40</sub> [105857-23-6].

#### DEFINITION

Alteplase is a highly purified glycosylated serine protease with fibrin-binding properties and plasminogen-specific proteolytic activities. It is produced by recombinant DNA synthesis in mammalian cell culture. It has a biological potency of NLT 90.0% and NMT 115.0% of the potency stated on the label, the potency being 580,000 USP Alteplase Units/mg of protein.

The presence of host cell DNA and host cell protein impurities in Alteplase is process specific; the limits of these impurities are determined by validated methods.

#### IDENTIFICATION

• A.

Standard solution: 1.0–2.5 mg/mL of USP Alteplase RS Sample solution: Prepare similarly to the Standard solution.

#### Result = $(R_U/R_S) \times (C_S/C_U) \times 100$

- = peak response ratio of alprostadil to the  $R_U$ internal standard from the Sample solution
- = peak response ratio of alprostadil to the Rs internal standard from the Standard solution
- = concentration of USP Alprostadil RS in the Cs Standard solution (mg/mL)
- = nominal concentration of alprostadil the  $C_U$ Sample solution (mg/mL)

Acceptance criteria: 90.0%-115.0%

### SPECIFIC TESTS

- BACTERIAL ENDOTOXINS TEST (85): It contains NMT 5 USP Endotoxin Units/100  $\mu$ g of alprostadil.
- STERILITY TESTS (71): It meets the requirements when tested as directed in Test for Sterility of the Product to Be Examined, Membrane Filtration.
- WATER DETERMINATION, Method I (921): NMT 0.4%
- OTHER REQUIREMENTS: It meets the requirements in Injections and Implanted Drug Products (1).

#### ADDITIONAL REQUIREMENTS

#### Analysis

**Samples:** Standard solution and Sample solution To each of three test tubes transfer 1 mL of 0.5-mg/mL H-D-isoleucyl-prolyl-arginyl-p-nitroaniline dihydrochloride. Separately transfer 200  $\mu$ L of the Standard solution and 200  $\mu$ L of the Sample solution to two of the test tubes. To the third test tube add 200 µL of 0.2 M arginine solution that has been adjusted with phosphoric acid to a pH of 7.3 (negative control). Mix the solutions in the three test tubes, and allow to stand for 1 min.

Acceptance criteria: A yellow color is produced in the solutions from the Standard solution and the Sample so*lution,* while no yellow color is produced in the negative control.

#### • **B. PEPTIDE MAPPING**

Solution A: 6.9 mg/mL of monobasic sodium phosphate in water, adjusted with phosphoric acid to a pH of 2.85. Filter, and degas. Solution B: Acetonitrile Mobile phase: See Table 1.

(ISB)

59,007.61

• PACKAGING AND STORAGE: Preserve in tight, single-dose containers, preferably of Type I glass. Store in a refrigerator.

โล	bl	e	1
----	----	---	---

Time (min)	Solution A (%)	Solution B (%)
0	100	0
91	70	30
121	40	<u>6</u> 0
131	40	60